Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy.

Louis Jeune V, Joergensen JA, Hajjar RJ, Weber T.

Hum Gene Ther Methods. 2013 Apr;24(2):59-67. doi: 10.1089/hgtb.2012.243. Epub 2013 Apr 3. Review.

2.

Targeted modifications in adeno-associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo.

Sen D, Gadkari RA, Sudha G, Gabriel N, Kumar YS, Selot R, Samuel R, Rajalingam S, Ramya V, Nair SC, Srinivasan N, Srivastava A, Jayandharan GR.

Hum Gene Ther Methods. 2013 Apr;24(2):104-16. doi: 10.1089/hgtb.2012.195.

3.

Strategies to circumvent humoral immunity to adeno-associated viral vectors.

Tse LV, Moller-Tank S, Asokan A.

Expert Opin Biol Ther. 2015 Jun;15(6):845-55. doi: 10.1517/14712598.2015.1035645. Review.

4.

Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine.

McIntosh JH, Cochrane M, Cobbold S, Waldmann H, Nathwani SA, Davidoff AM, Nathwani AC.

Gene Ther. 2012 Jan;19(1):78-85. doi: 10.1038/gt.2011.64. Epub 2011 Jun 30.

5.

Humoral immunity to AAV vectors in gene therapy: challenges and potential solutions.

Masat E, Pavani G, Mingozzi F.

Discov Med. 2013 Jun;15(85):379-89. Review.

6.

Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors.

Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF, Masurier C.

Hum Gene Ther. 2010 Jun;21(6):704-12. doi: 10.1089/hum.2009.182.

PMID:
20095819
7.

Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue.

Mingozzi F, Chen Y, Edmonson SC, Zhou S, Thurlings RM, Tak PP, High KA, Vervoordeldonk MJ.

Gene Ther. 2013 Apr;20(4):417-24. doi: 10.1038/gt.2012.55. Epub 2012 Jul 12.

8.

Immunity to adeno-associated virus vectors in animals and humans: a continued challenge.

Zaiss AK, Muruve DA.

Gene Ther. 2008 Jun;15(11):808-16. doi: 10.1038/gt.2008.54. Epub 2008 Apr 3. Review.

PMID:
18385765
9.

Expressing Transgenes That Exceed the Packaging Capacity of Adeno-Associated Virus Capsids.

Chamberlain K, Riyad JM, Weber T.

Hum Gene Ther Methods. 2016 Feb;27(1):1-12. doi: 10.1089/hgtb.2015.140. Review.

10.

Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery.

Chicoine LG, Montgomery CL, Bremer WG, Shontz KM, Griffin DA, Heller KN, Lewis S, Malik V, Grose WE, Shilling CJ, Campbell KJ, Preston TJ, Coley BD, Martin PT, Walker CM, Clark KR, Sahenk Z, Mendell JR, Rodino-Klapac LR.

Mol Ther. 2014 Feb;22(2):338-47. doi: 10.1038/mt.2013.244. Epub 2013 Oct 23.

11.

Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector.

Bowles DE, McPhee SW, Li C, Gray SJ, Samulski JJ, Camp AS, Li J, Wang B, Monahan PE, Rabinowitz JE, Grieger JC, Govindasamy L, Agbandje-McKenna M, Xiao X, Samulski RJ.

Mol Ther. 2012 Feb;20(2):443-55. doi: 10.1038/mt.2011.237. Epub 2011 Nov 8.

12.

Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates.

Kotterman MA, Yin L, Strazzeri JM, Flannery JG, Merigan WH, Schaffer DV.

Gene Ther. 2015 Feb;22(2):116-26. doi: 10.1038/gt.2014.115. Epub 2014 Dec 11.

13.

Adeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them.

Hareendran S, Balakrishnan B, Sen D, Kumar S, Srivastava A, Jayandharan GR.

Rev Med Virol. 2013 Nov;23(6):399-413. doi: 10.1002/rmv.1762. Epub 2013 Sep 10. Review.

PMID:
24023004
14.

Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies.

Huttner NA, Girod A, Perabo L, Edbauer D, Kleinschmidt JA, Büning H, Hallek M.

Gene Ther. 2003 Dec;10(26):2139-47.

PMID:
14625569
15.

Naturally enveloped AAV vectors for shielding neutralizing antibodies and robust gene delivery in vivo.

György B, Fitzpatrick Z, Crommentuijn MH, Mu D, Maguire CA.

Biomaterials. 2014 Aug;35(26):7598-609. doi: 10.1016/j.biomaterials.2014.05.032. Epub 2014 Jun 7.

16.

Bioengineering of AAV2 capsid at specific serine, threonine, or lysine residues improves its transduction efficiency in vitro and in vivo.

Gabriel N, Hareendran S, Sen D, Gadkari RA, Sudha G, Selot R, Hussain M, Dhaksnamoorthy R, Samuel R, Srinivasan N, Srivastava A, Jayandharan GR.

Hum Gene Ther Methods. 2013 Apr;24(2):80-93. doi: 10.1089/hgtb.2012.194. Epub 2013 Mar 15.

17.

The complex and evolving story of T cell activation to AAV vector-encoded transgene products.

Mays LE, Wilson JM.

Mol Ther. 2011 Jan;19(1):16-27. doi: 10.1038/mt.2010.250. Epub 2010 Nov 30. Review.

18.

Neutralizing antibodies against adeno-associated viruses in inflammatory bowel disease patients: implications for gene therapy.

van der Marel S, Comijn EM, Verspaget HW, van Deventer S, van den Brink GR, Petry H, Hommes DW, Ferreira V.

Inflamm Bowel Dis. 2011 Dec;17(12):2436-42. doi: 10.1002/ibd.21673. Epub 2011 Mar 2.

PMID:
21370319
19.
20.

Immune responses to adeno-associated virus vectors.

Zaiss AK, Muruve DA.

Curr Gene Ther. 2005 Jun;5(3):323-31. Review.

PMID:
15975009

Supplemental Content

Support Center